Virtual Meeting
Sobi is committed to providing you with ongoing support

Schedule a virtual discussion with a Gamifant Health Systems Director today.


Gamifant® (emapalumab-lzsg) was proven to be effective in a clinical trial1

For patients with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.


63% overall response rate (ORR) with Gamifant1

(95% CI: 0.42, 0.81; P = 0.013)

  • ORR is defined as achievement of either complete or partial response in HLH improvement1
  • Median time to response was 8 days and responses were generally maintained2
  • Median duration of first response, defined as time from achievement of first response to loss of first response, was not reached1

70% of patients (19/27) proceeded to HSCT1


Gamifant was shown to neutralize IFNγ1,2

Gamifant was shown to neutralize IFNγ as measured by a rapid and sustained reduction in the plasma concentrations of CXCL9, a chemokine induced almost exclusively by IFNγ. This is consistent with the early onset of clinical action and time to response seen with Gamifant.

See how Gamifant works